In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy. Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection based on patient age, prior therapy, drug exposure, and disease biology The importance of shared decision-making and incorporating patient preferences into treatment planning Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today&#x27;s evolving treatment landscape. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

Oncology Brothers: Practice-Changing Cancer Discussions

Hello and welcome back to the Oncology Brothers Podcast. I'm Rohit Ghossain alongside my brother and co-host Raval Ghossain. Today we continue our treatment algorithm series where we are focusing on Early Relapsed/Refractory Multiple Myeloma. In our prior discussion on multiple myeloma, we touched on frontline treatment option and maintenance treatment option. Today we're talking about our options if the disease was to progress on frontline settings. For this, we're excited to

have Dr. Shaji Kumar, a myeloma specialist from Mayo Clinic. Shaji, thanks so much for joining us. Shaji, welcome. To lay the foundation here in frontline settings, we start off with quad therapy for all our patients with myeloma and we can dose adjust for that frail patients. But quad therapy here with anti-CD38, proteasome inhibitors, lenalidomide and DEX is now the standard of care. Then for maintenance, we have lenalidomide for two years based off endurance trial led by you.

This is for standard risk cytogenetics. For high risk cytogenetics, Dara-Rav lifelong still remains the standard of care. But what next if the disease was to progress or relapse after that maintenance therapy? Here we have one CAR-T and then Teclistimab + Daratumumab based off Majestic 3 study. But very likely we'll see approval of teclastimab by itself based off Majestic 9 here. But we also have data for telcretimab

based off Monumental 3. And days ago, we also saw a press release for Monumental 6 where teclastimab, a BCMA-directed, and telquetimab, a GPRC5D-directed by specific antibodies are being combined in this space. Shaji, today, can you touch on how do you pick one option over another here, keeping if the disease is len-and-dera exposed versus this disease being refractory to these options?

Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.